Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key

A combination of tyrosine kinase inhibitors (TKIs) is likely to be a therapeutic option for numerous oncological situations due to high frequency of oncogenic addiction and progress in precision oncology. Non-small cell lung cancer (NSCLC) represents a subtype of tumors for which oncogenic drivers a...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Quentin Dominique, Firmin, Nelly, Mbatchi, Litaty, Evrard, Alexandre, Quantin, Xavier, Leenhardt, Fanny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054357/
https://www.ncbi.nlm.nih.gov/pubmed/36982592
http://dx.doi.org/10.3390/ijms24065518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054357/
https://www.ncbi.nlm.nih.gov/pubmed/36982592
http://dx.doi.org/10.3390/ijms24065518

Ejemplares similares